prothymosin alpha is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-01-15. Where a claim depends on a specific study, the study is described rather than over-claimed.
Immune signaling studies link thymosin alpha 1 to Toll-like receptor pathways, particularly TLR2 and TLR9, on dendritic cells and other antigen-presenting cells. Activation of these receptors promotes maturation of T cells and increases natural killer cell activity. The peptide shifts cytokine output toward a T helper 1 profile, raising interferon gamma and interleukin 2 while modulating interleukin 10. Whether these effects translate into clinical benefit for any specific disease remains a subject of debate. Reported outcomes vary across trials and populations.
Thymosin alpha 1 is approved as a medicine in several countries, including Italy and China, for indications such as chronic hepatitis B and as an immune adjuvant. It is not approved by the United States Food and Drug Administration as a therapeutic product. In research settings the peptide appears in studies of sepsis, vaccine response, and oncology support, often with mixed or inconclusive results. The evidence base is uneven, and reviews note that many trials were small. Regulatory status therefore differs widely between jurisdictions.
Thymosin alpha 1 is a synthetic 28-amino-acid peptide first isolated in 1966 from thymosin fraction 5, a bovine thymus extract. Its chain begins with an acetylated serine residue and ends with asparagine. The native peptide carries a molecular mass near 3,108 daltons. Researchers classify it as an immunomodulatory agent rather than a hormone with a single endocrine target. Early work framed it as a thymus-derived factor that supports T-cell maturation. The synthetic form used in research and clinical products matches the natural sequence.
Thymosin alpha 1 is a 28-amino-acid peptide first isolated from thymosin fraction 5, a bovine thymic extract. Its sequence begins with an acetylated serine residue and carries a high proportion of acidic residues, so the molecule has a net negative charge near neutral pH. Despite the shared name, it is unrelated in sequence to the thymosin beta family. Synthetic material prepared by solid-phase peptide synthesis is identical in sequence to the natural peptide.
Several names appear in the literature for this peptide, including thymalfasin and the abbreviation T-alpha-1. Naming conventions differ among research articles, regulatory documents, and supplier catalogs, which complicates literature searches. Both synthetic and recombinant production routes yield a peptide with the same 28-residue sequence as the thymic isolate. Because the thymosin label also covers unrelated peptides, sources should be compared by sequence rather than by name alone.
| Property | Value | Notes |
|---|---|---|
| Molecular mass | ≈3,108 Da | Synthetic 28-residue peptide |
| Amino acid count | 28 | N-terminal serine carries an acetyl group |
| Appearance | White to off-white powder | Lyophilized solid |
| Water solubility | Freely soluble | Dissolves in aqueous buffer |
| Common synonyms | Thymalfasin; Tα1 | Thymalfasin is the international nonproprietary name |
== High-pressure freezing == High pressure helps prevent the formation of large ice crystals. Self pressurized rapid freezing (SPRF) can utilize many different cryogens has recently been touted as an attractive and low cost alternative to high pressure freezing (HPF). Cold pressurized nitrogen substitutes ethanol at temperatures roughly 123K. The warm ethanol is then expelled by the freezing LN2 and most likely produces an ethanol-nitrogen mixture that gradually becomes colder and colder.
== Properties == The properties of a material in nanoparticle form are unusually different from those of the bulk one even when divided into micrometer-size particles. Many of them arise from spatial confinement of sub-atomic particles (i.e. electrons, protons, photons) and electric fields around these particles. The large surface to volume ratio is also significant factor at this scale.
It is said that a person, once he has drunk umm nyolokh, will return to giraffe again and again. Humr, being Mahdists, are strict abstainers [from alcohol] and a Humrawi is never drunk (sakran) on liquor or beer. But he uses this word to describe the effects which umm nyolokh has upon him. Cunnison's remarkable account of an apparently psychoactive mammal found its way from a somewhat obscure scientific paper into more mainstream literature through a conversation between W. James of the Institute of Social and Cultural Anthropology at the University of Oxford and specialist on the use of hallucinogens and intoxicants in society, and R. Rudgley, who discussed it in a book on psychoactive drugs for general readers. He speculated that a hallucinogenic compound, dimethyltryptamine (DMT), of the Giraffa (giraffe) liver might account for benevolent claims of intoxicating beverages (and potentially herbs), such as a beverage (African: umm nyolokh) used by the Arab people of Sudan like a potion. Cunnison wrote in 1958 that found it hard to believe in the literal truth of the Humr's assertion that the drink was intoxicating:
Sources: en.wikipedia.org
In February 2015, Labcorp acquired Covance for $6.1 billion. In October 2015, Labcorp acquired Safe Foods International Holdings and its two operating companies, International Food Network and The National Food Laboratory, expanding its capabilities in food and beverage product-development and product-integrity. In March 2016, Labcorp acquired Pathology Inc., a provider of reproductive donor testing as well as anatomic, molecular and digital pathology services focused on women's health. In September 2016, Labcorp acquired Sequenom for $371 million including debt, expanding its operations in Europe and Asia. In October 2016, Labcorp acquired ClearPath Diagnostics, a provider of laboratory diagnostic services in the Northeastern United States, from Shore Capital Partners. In May 2017, Labcorp acquired Pathology Associates Medical Laboratories from Providence Health & Services and Catholic Health Initiatives. In September 2017, Labcorp acquired Chiltern, a contract research organization (CRO), for $1.2 billion, and contributed it to Covance. In 2019, Labcorp acquired Wellness Corporate Solutions, a workplace wellness company.
== Instrumentation == FTICR-MS differs significantly from other mass spectrometry techniques in that the ions are not detected by hitting a detector such as an electron multiplier but only by passing near detection plates. Additionally the masses are not resolved in space or time as with other techniques but only by the ion cyclotron resonance (rotational) frequency that each ion produces as it rotates in a magnetic field. Thus, the different ions are not detected in different places as with sector instruments or at different times as with time-of-flight instruments, but all ions are detected simultaneously during the detection interval. This provides an increase in the observed signal-to-noise ratio owing to the principles of Fellgett's advantage. In FTICR-MS, resolution can be improved either by increasing the strength of the magnet (in teslas) or by increasing the detection duration.
oxidized ferredoxin + NADH + H+ Thus, the two substrates of this enzyme are reduced ferredoxin and NAD+, whereas its 3 products are oxidized ferredoxin, NADH, and H+. This enzyme participates in fatty acid metabolism. This enzyme belongs to the family of oxidoreductases, specifically those acting on iron-sulfur proteins as donor with NAD+ or NADP+ as acceptor. The systematic name of this enzyme is ferredoxin:NAD+ oxidoreductase. There are a variety of names in common use:
Sources: en.wikipedia.org
It is a chain of 28 amino acids, with an acetyl group attached to the first serine residue. The synthetic version replicates this sequence. Its molecular mass is about 3,108 daltons.
It is usually described as an immunomodulatory peptide rather than a classic hormone. It acts on immune cells through receptor pathways. No single endocrine organ target defines its function.
Several countries, including Italy and China, allow it for specific indications. The FDA has not approved it as a drug in the United States. Availability depends on local regulation.
It is a 28-amino-acid peptide originally purified from a bovine thymic extract and later produced synthetically. It is studied mainly for its effects on immune cell function.